Table 1.
Vaccine Samples | Triton X-114 | Endotrap Resin | Purification conditions | CTB-INS protein recovery (%) | Endotoxin levels (EU/mL) |
---|---|---|---|---|---|
CTB-INS | − | − | D | 100 | 66,700 |
CTB-INS | − | + | D | 77.9 | 1.3 |
CTB-INS | + | − | D | 86.1 | 1.1 |
CTB-INS | + | + | D | 55.6 | 0.01 |
Removal of residual LPS endotoxin from CTB-INS protein isolated from E. coli. Partially purified recombinant CTB-INS fusion protein was isolated from sonicated E. coli BL-21 cells by nickel – agarose (Ni-NTA) affinity column chromatography under denaturing conditions of 8.0 M urea (D). Residual LPS was removed from the partially purified CTB-INS protein by treatment with 0.1% Triton X-114 or by passage of the protein over an Endotrap resin column. For maximum endotoxin removal, CTB-INS protein was purified by treatment with Triton X-114 followed by treatment with Endotrap resin.